KEAP1 and non-small cell lung carcinoma: Our results demonstrate that the combined treatment of Canagliflozin and Brusatol exerts potent anti-tumour effects in LKB1-KEAP1 co-mutant NSCLC cells both <i>in vitro</i> and <i>in vivo</i>.